India will procure 20 more doses of monoclonal antibody for the treatment of Nipah virus infection from Australia, ICMR Director-General Rajeev Bahl said on Friday.
“We got some doses of monoclonal antibody from Australia in 2018. Currently the doses are available for only 10 patients,” he said.
According to him, no one so far has been administered the medicine in India.
“Twenty more doses are being procured. But the medicine needs to be given during the early stage of the infection,” he said, adding it can only given as compassionate use medicine.
Mr. Bahl also said mortality among the infected is very high in the case of Nipah virus (between 40 and 70%) compared to the mortality of COVID-19, which was 2-3%.
He asserted that all efforts are underway to contain the spread of the virus in Kerala.
All patients are contact of an index patient, he said.
On why cases keep surfacing in Kerala, Mr. Bahl said, “We do not know. In 2018, we found the outbreak in Kerala was related to bats. We are not sure how the infection passed from bats to humans. The link couldn’t be established. Again we are trying to find out this time. It always happens in the rainy season.” He said monoclonal antibody has been given to 14 patients infected with Nipah outside India and all of them have survived.
“Only phase 1 trial to establish the safety of the medicine has been done outside. Efficacy trials have not been done. It can only given as compassionate use medicine,” he said.
Globally, monoclonal antibody have been given to 14 patients infected with Nipah outside India and all of them have survived.
The decision to use the antibody, however, has to be of the Kerala government’s, besides that of doctors and also families of patients.
